{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-011839","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.264315+00:00","generated_at":"2026-05-24T23:44:59.299313+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025","bullets":["Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.","Cash & securities $53.1M expected to fund operations into H2 2026.","Topline Phase 1 results for OV329 (GABA-AT inhibitor) expected Q3 2025; no SAEs to date.","OV350 (first KCC2 direct activator) began Phase 1 in Q1 2025; topline data expected Q4 2025.","Stelios Papadopoulos appointed to Board; Manal Morsy (Chief Regulatory Officer) and Victoria Fort (Corporate Affairs) joined."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-011839","json":"https://secwatch.observer/filing/0001628280-25-011839.json","markdown":"https://secwatch.observer/filing/0001628280-25-011839.md","text":"https://secwatch.observer/filing/0001628280-25-011839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/0001628280-25-011839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:44:59.299313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}